Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
30
IFRX Quote, Financials, Valuation and Earnings
Last price:
$1.02
Seasonality move
:
7.86%
Day range:
$0.99 - $1.03
52-week range:
$0.71 - $2.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
312.07x
P/B ratio:
1.28x
Volume:
595.6K
Avg. volume:
786.3K
1-year change:
-59.11%
Market cap:
$68.4M
Revenue:
$179.3K
EPS (TTM):
-$0.92
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$30.8K | -$0.16 | -74.55% | -16.09% | $11.25 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$1.5M | -$0.96 | -7.14% | -109.39% | $53.71 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-- | -$0.67 | -100% | -499.94% | $46.56 |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.63 | -- | -1.78% | $49.45 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$1.01 | $11.25 | $68.4M | -- | $0.00 | 0% | 312.07x |
|
CDT
CDT Equity, Inc.
|
$1.28 | -- | $2.1M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$16.00 | $53.71 | $500.6M | -- | $1.03 | 0% | 25.52x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$41.43 | $46.56 | $2B | -- | $0.00 | 0% | 501.13x |
|
ORKA
Oruka Therapeutics, Inc.
|
$30.31 | $49.45 | $1.5B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
2.1% | -0.265 | 1.26% | 2.34x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or CDT?
CDT Equity, Inc. has a net margin of -51538.49% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -82.01% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-320.86% -$0.21 $54.4M CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About IFRX or CDT?
InflaRx NV has a consensus price target of $11.25, signalling upside risk potential of 1013.96%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than CDT Equity, Inc., analysts believe InflaRx NV is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 2 0 CDTCDT Equity, Inc.0 0 0 -
Is IFRX or CDT More Risky?
InflaRx NV has a beta of 1.443, which suggesting that the stock is 44.312% more volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CDT?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CDT?
InflaRx NV quarterly revenues are $27.8K, which are larger than CDT Equity, Inc. quarterly revenues of --. InflaRx NV's net income of -$14.3M is lower than CDT Equity, Inc.'s net income of -$7.1M. Notably, InflaRx NV's price-to-earnings ratio is -- while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 312.07x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV312.07x -- $27.8K -$14.3M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns IFRX or LENZ?
LENZ Therapeutics, Inc. has a net margin of -51538.49% compared to InflaRx NV's net margin of -133.6%. InflaRx NV's return on equity of -82.01% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-320.86% -$0.21 $54.4M LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About IFRX or LENZ?
InflaRx NV has a consensus price target of $11.25, signalling upside risk potential of 1013.96%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.71 which suggests that it could grow by 235.71%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, Inc., analysts believe InflaRx NV is more attractive than LENZ Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 2 0 LENZLENZ Therapeutics, Inc.6 0 0 -
Is IFRX or LENZ More Risky?
InflaRx NV has a beta of 1.443, which suggesting that the stock is 44.312% more volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LENZ?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. InflaRx NV pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LENZ?
InflaRx NV quarterly revenues are $27.8K, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. InflaRx NV's net income of -$14.3M is higher than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, InflaRx NV's price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 312.07x versus 25.52x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV312.07x -- $27.8K -$14.3M LENZLENZ Therapeutics, Inc.25.52x -- $12.5M -$16.7M
-
Which has Higher Returns IFRX or LIMN?
Liminatus Pharma has a net margin of -51538.49% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -82.01% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-320.86% -$0.21 $54.4M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About IFRX or LIMN?
InflaRx NV has a consensus price target of $11.25, signalling upside risk potential of 1013.96%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Liminatus Pharma, analysts believe InflaRx NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 2 0 LIMNLiminatus Pharma0 0 0 -
Is IFRX or LIMN More Risky?
InflaRx NV has a beta of 1.443, which suggesting that the stock is 44.312% more volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LIMN?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LIMN?
InflaRx NV quarterly revenues are $27.8K, which are larger than Liminatus Pharma quarterly revenues of --. InflaRx NV's net income of -$14.3M is higher than Liminatus Pharma's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 312.07x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV312.07x -- $27.8K -$14.3M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns IFRX or MAZE?
Maze Therapeutics, Inc. has a net margin of -51538.49% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -82.01% beat Maze Therapeutics, Inc.'s return on equity of -35.16%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-320.86% -$0.21 $54.4M MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M -
What do Analysts Say About IFRX or MAZE?
InflaRx NV has a consensus price target of $11.25, signalling upside risk potential of 1013.96%. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $46.56 which suggests that it could grow by 12.37%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, Inc., analysts believe InflaRx NV is more attractive than Maze Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 2 0 MAZEMaze Therapeutics, Inc.9 0 0 -
Is IFRX or MAZE More Risky?
InflaRx NV has a beta of 1.443, which suggesting that the stock is 44.312% more volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or MAZE?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or MAZE?
InflaRx NV quarterly revenues are $27.8K, which are larger than Maze Therapeutics, Inc. quarterly revenues of --. InflaRx NV's net income of -$14.3M is higher than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, InflaRx NV's price-to-earnings ratio is -- while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 312.07x versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV312.07x -- $27.8K -$14.3M MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M
-
Which has Higher Returns IFRX or ORKA?
Oruka Therapeutics, Inc. has a net margin of -51538.49% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -82.01% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-320.86% -$0.21 $54.4M ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About IFRX or ORKA?
InflaRx NV has a consensus price target of $11.25, signalling upside risk potential of 1013.96%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $49.45 which suggests that it could grow by 63.16%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, Inc., analysts believe InflaRx NV is more attractive than Oruka Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 2 0 ORKAOruka Therapeutics, Inc.10 0 0 -
Is IFRX or ORKA More Risky?
InflaRx NV has a beta of 1.443, which suggesting that the stock is 44.312% more volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.394, suggesting its less volatile than the S&P 500 by 139.44%.
-
Which is a Better Dividend Stock IFRX or ORKA?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. InflaRx NV pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ORKA?
InflaRx NV quarterly revenues are $27.8K, which are larger than Oruka Therapeutics, Inc. quarterly revenues of --. InflaRx NV's net income of -$14.3M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, InflaRx NV's price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 312.07x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV312.07x -- $27.8K -$14.3M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
